|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ciombor KK, Wu C and Goldberg RM: Recent
therapeutic advances in the treatment of colorectal cancer. Annu
Rev Med. 66:83–95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ren A, Dong Y, Tsoi H and Yu J: Detection
of miRNA as non-invasive biomarkers of colorectal cancer. Int J Mol
Sci. 16:2810–2823. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zeng CY, Zhan YS, Huang J and Chen YX:
MicroRNA-7 suppresses human colon cancer invasion and proliferation
by targeting the expression of focal adhesion kinase. Mol Med Rep.
13:1297–1303. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Slaby O: Non-coding RNAs as biomarkers for
colorectal cancer screening and early detection. Adv Exp Med Biol.
937:153–170. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang L, Cheng Q, Zhang BH and Zhang MZ:
Circulating microRNAs as biomarkers in hepatocellular carcinoma
screening: A validation set from China. Medicine (Baltimore).
94:e6032015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khoury S and Tran N: Circulating
microRNAs: Potential biomarkers for common malignancies. Biomark
Med. 9:131–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He N, Zheng H, Li P, Zhao Y, Zhang W, Song
F and Chen K: miR-485-5p binding site SNP rs8752 in HPGD gene is
associated with breast cancer risk. PLoS One. 9:e1020932014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim TH, Kim YK, Kwon Y, Heo JH, Kang H,
Kim G and An HJ: Deregulation of miR-519a, 153, and 485-5p and its
clinicopathological relevance in ovarian epithelial tumours.
Histopathology. 57:734–743. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang M, Ren MP, Zhao L, Li CP and Deng MM:
miR-485-5p acts as a negative regulator in gastric cancer
progression by targeting flotillin-1. Am J Transl Res. 7:2212–2222.
2015.PubMed/NCBI
|
|
11
|
Chen Z, Li Q, Wang S and Zhang J:
miR-485-5p inhibits bladder cancer metastasis by targeting HMGA2.
Int J Mol Med. 36:1136–1142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rosenthal EL, Shreenivas S, Peters GE,
Grizzle WE, Desmond R and Gladson CL: Expression of extracellular
matrix metalloprotease inducer in laryngeal squamous cell
carcinoma. Laryngoscope. 113:1406–1410. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gallagher SM, Castorino JJ, Wang D and
Philp NJ: Monocarboxylate transporter 4 regulates maturation and
trafficking of CD147 to the plasma membrane in the metastatic
breast cancer cell line MDA-MB-231. Cancer Res. 67:4182–4189. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sato M, Nakai Y, Nakata W, Yoshida T,
Hatano K, Kawashima A, Fujita K, Uemura M, Takayama H and Nonomura
N: EMMPRIN promotes angiogenesis, proliferation, invasion and
resistance to sunitinib in renal cell carcinoma, and its level
predicts patient outcome. PLoS One. 8:e743132013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Omi Y, Shibata N, Okamoto T, Obara T and
Kobayashi M: The role of CD147 in the invasiveness of follicular
thyroid carcinoma cells. Thyroid. 22:383–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stenzinger A, Wittschieber D, von
Winterfeld M, Goeppert B, Kamphues C, Weichert W, Dietel M, Rabien
A and Klauschen F: High extracellular matrix metalloproteinase
inducer/CD147 expression is strongly and independently associated
with poor prognosis in colorectal cancer. Hum Pathol. 43:1471–1481.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu S, Chu D, Zhang Y, Wang X, Gong L, Han
X, Yao L, Lan M, Li Y and Zhang W: EMMPRIN/CD147 expression is
associated with disease-free survival of patients with colorectal
cancer. Med Oncol. 30:3692013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng HC, Wang W, Xu XY, Xia P, Yu M,
Sugiyama T and Takano Y: Up-regulated EMMPRIN/CD147 protein
expression might play a role in colorectal carcinogenesis and its
subsequent progression without an alteration of its glycosylation
and mRNA level. J Cancer Res Clin Oncol. 137:585–596. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pan Y, He B, Song G, Bao Q, Tang Z, Tian F
and Wang S: CD147 silencing via RNA interference reduces tumor cell
invasion, metastasis and increases chemosensitivity in pancreatic
cancer cells. Oncol Rep. 27:2003–2009. 2012.PubMed/NCBI
|
|
20
|
Pan Y, He B, Chen J, Sun H, Deng Q, Wang
F, Ying H, Liu X, Lin K, Peng H, et al: Gene therapy for colorectal
cancer by adenovirus-mediated siRNA targeting CD147 based on loss
of the IGF2 imprinting system. Int J Oncol. 47:1881–1889. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gray RT, Coleman HG, Hughes C, Murray LJ
and Cardwell CR: Statin use and survival in colorectal cancer:
Results from a population-based cohort study and an updated
systematic review and meta-analysis. Cancer Epidemiol. 45:71–81.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y
and Li Z: miR-485-3p and miR-485-5p suppress breast cancer cell
metastasis by inhibiting PGC-1α expression. Cell Death Dis.
7:e21592016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guo GX, Li QY, Ma WL, Shi ZH and Ren XQ:
MicroRNA-485-5p suppresses cell proliferation and invasion in
hepatocellular carcinoma by targeting stanniocalcin 2. Int J Clin
Exp Pathol. 8:12292–12299. 2015.PubMed/NCBI
|
|
24
|
Li R, Pan Y, He B, Xu Y, Gao T, Song G,
Sun H, Deng Q and Wang S: Downregulation of CD147 expression by RNA
interference inhibits HT29 cell proliferation, invasion and
tumorigenicity in vitro and in vivo. Int J Oncol.
43:1885–1894. 2013. View Article : Google Scholar : PubMed/NCBI
|
